BIOMODEX Technology Enables New Milestone in Interventional Cardiology

BIOMODEX, the leader in bio-realistic haptic simulators for patient-specific rehearsal and physician training, today announced that its LAACS™ (Left Atrial Appendage Closure System) solution was used to perform a simulation ahead of a live case to be presented at the TVT Structural Heart Summit in Miami, FL.

Physicians at the Montreal Heart Institute in Montreal, Quebec recently rehearsed the full procedure of a Left Atrial Appendage Occlusion (LAAO) for the first time in North America using a bio-realistic haptic simulator. This breakthrough was achieved by Dr. Reda Ibrahim (interventional cardiologist), Dr. Blandine Mondesert (electrophysiologist), and Dr. Walid Ben Ali (cardiac surgeon) utilizing a 3D-printed replica of the patient’s heart. This replica is part of a novel simulator that delivers realistic catheter navigation, haptic feedback, transesophageal echography, and fluoroscopic imaging.

“Rehearsing a specific case was very helpful—especially one in which we used innovative technologies like the new Abbott Steerable Delivery Sheath for the Amplatzer Amulet occluder, and the transseptal VersaCross Baylis System,” said Dr. Ibrahim. “This realistic simulation allowed us to maximize procedural success and safety.”

For this case, Biomodex printed a 3D patient-specific cardiac anatomy based on the patient’s own CTA images. Models are made of advanced materials that simulate the biomechanical characteristics and haptic feedback of the anatomy. Furthermore, the LAACS station replicates blood flow and viscosity and is ultrasound compatible. The simulation is intended to boost physician confidence, reduce operating times, and decrease the risk of complications.

Cardiovascular transcatheter therapies have transformed the treatment landscape, expanding options for patients with structural heart disease.

“Rehearsing these novel approaches using a patient-specific anatomical model is intended to better prepare physicians and potentially improve patient outcomes,” said Ziad Rouag, President and Chief Executive Officer of Biomodex. “It was an honor to support Dr. Ibrahim and his team.”

The rehearsal and subsequent live patient procedure were performed and recorded at the Montreal Heart Institute. Dr. Ibrahim and his team will present their live case at TVT 2021: The Structural Heart Summit on July 22 from 9:30am to 10:10am EDT (LAA Live Case #20: Update of Left Atrial Appendage Occlusion). To register, visit here.

SourceBIOMODEX

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”